Fluicell Past Earnings Performance

Past criteria checks 0/6

Fluicell's earnings have been declining at an average annual rate of -8.4%, while the Medical Equipment industry saw earnings declining at 1.1% annually. Revenues have been declining at an average rate of 4.4% per year.

Key information

-8.4%

Earnings growth rate

28.1%

EPS growth rate

Medical Equipment Industry Growth4.3%
Revenue growth rate-4.4%
Return on equity-107.9%
Net Margin-1,422.9%
Next Earnings Update07 Mar 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Fluicell makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:5J9 Revenue, expenses and earnings (SEK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 242-22260
30 Jun 241-27280
31 Mar 242-29300
31 Dec 233-27290
30 Sep 235-25290
30 Jun 235-22290
31 Mar 234-22290
31 Dec 223-22270
30 Sep 222-20260
30 Jun 223-22260
31 Mar 223-21240
31 Dec 213-22240
30 Sep 213-21240
30 Jun 212-21230
31 Mar 214-19220
31 Dec 205-18200
30 Sep 204-18210
30 Jun 204-17200
31 Mar 203-18200
31 Dec 192-19200
30 Sep 192-18190
30 Jun 192-17180
31 Mar 192-16170
31 Dec 181-15150
30 Sep 182-12130
30 Jun 182-11110
31 Mar 181-990
31 Dec 171-780
31 Dec 163-560
31 Dec 151-320
31 Aug 140-220

Quality Earnings: 5J9 is currently unprofitable.

Growing Profit Margin: 5J9 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 5J9 is unprofitable, and losses have increased over the past 5 years at a rate of 8.4% per year.

Accelerating Growth: Unable to compare 5J9's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 5J9 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (10.1%).


Return on Equity

High ROE: 5J9 has a negative Return on Equity (-107.95%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 15:07
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Fluicell AB (publ) is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution